# US 2016/0353789 A1 · Nutrition composition suppressing growth of protozoan parasites of blood cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0353789 A1
- Document ID: US20160353789A1
- Status: Published application
- Kind: A1
- Application number: 15/244,349
- Filed: 2016-08-23
- Published: 2016-12-08
- Earliest claimed: 2014-02-24
- Assignees: Ajinomoto Co., Inc.
- Applicants: Ajinomoto Co., Inc.
- Inventors: Makoto BANNAI; Kenji Nagao; Hirotaka Kanuka
- Web page: https://patentgrep.com/patent/US20160353789A1

## CPC

- A23L 33/175: Amino acids
- A23L 33/00: Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/4172: Imidazole-alkanecarboxylic acids, e.g. histidine
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/06: Antimalarials
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23V 2250/06: Amino acid
- A23V 2250/0626: Isoleucine
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Compositions, comprising one or more amino acids selected from the group consisting of tryptophan, methionine, phenylalanine, valine, leucine, histidine, lysine and threonine, and isoleucine at a content of not more than 1.5 wt % relative to the total amount of the nutrition composition, provide a more economical and effective nutrition composition for suppressing the growth of hemocytozoon such as malaria parasite and the like.

## Claims

### Claim 1

A nutrition composition, comprising:
(a) tryptophan, methionine, phenylalanine, valine, leucine, histidine, lysine, and threonine; and
(b) optionally isoleucine, wherein when said isoleucine is present, it is present in an amount of not more than 1.5 wt % relative to the total amount of the nutrition composition.

### Claim 2

A nutrition composition, comprising:
(a) tryptophan, methionine, phenylalanine, valine, leucine, histidine, lysine, and threonine; and
(b) optionally isoleucine, wherein when said isoleucine is present, it is present in an amount of not more than 3.8 wt % relative to the total amount of the amino acids.

### Claim 3 (depends on 1)

The nutrition composition according to claim 1, which does not contain isoleucine.

### Claim 4 (depends on 2)

The nutrition composition according to claim 2, which does not contain isoleucine.

### Claim 5 (depends on 1)

The nutrition composition according to claim 1, further comprising one or more nutrients selected from the group consisting of carbohydrate, protein, fat, vitamin and mineral.

### Claim 6 (depends on 2)

The nutrition composition according to claim 2, further comprising one or more nutrients selected from the group consisting of carbohydrate, protein, fat, vitamin and mineral.

### Claim 7

A method of suppressing the growth of a hemocytozoon, comprising administering, to a vertebrate in need thereof, an effective amount of a nutrition composition comprising:
(a) one or more amino acids selected from the group consisting of tryptophan, methionine, phenylalanine, valine, leucine, histidine, lysine, and threonine; and
(b) optionally isoleucine, wherein when said isoleucine is present, it is present in an amount of not more than 1.5 wt % relative to the total amount of the nutrition composition.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the nutrition composition does not contain isoleucine.

### Claim 9 (depends on 7)

The method according to claim 7, further comprising one or more nutrients selected from the group consisting of carbohydrate, protein, fat, vitamin and mineral.

### Claim 10 (depends on 7)

The method according to claim 7, wherein the hemocytozoon is a malaria parasite.

### Claim 11 (depends on 7)

The method according to claim 7, further comprising administering an effective amount of other antimalarial agent(s).

### Claim 12 (depends on 11)

The method according to claim 11, wherein said other antimalarial agent is one or more medicaments selected from the group consisting of quinine hydrochloride, chloroquine, mefloquine, a sulfadoxine/pyrimethamine combination agent, an atovaquone/proguanil combination agent, artemisinin, artesunate, artemether, an artemether/lumefantrine combination agent and an artesunate/amodiaquine combination agent.

### Claim 13

A method of suppressing the growth of a hemocytozoon, comprising administering, to a vertebrate in need thereof, an effective amount of a nutrition composition comprising:
(a) one or more amino acids selected from the group consisting of tryptophan, methionine, phenylalanine, valine, leucine, histidine, lysine, and threonine; and
(b) optionally isoleucine, wherein when said isoleucine is present, it is present in an amount of not more than 3.8 wt % relative to the total amount of the amino acids.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the nutrition composition does not contain isoleucine.

### Claim 15 (depends on 13)

The method according to claim 13, further comprising one or more nutrients selected from the group consisting of carbohydrate, protein, fat, vitamin and mineral.

### Claim 16 (depends on 13)

The method according to claim 13, wherein the hemocytozoon is a malaria parasite.

### Claim 17 (depends on 13)

The method according to claim 13, further comprising administering an effective amount of other antimalarial agent(s).

### Claim 18 (depends on 17)

The method according to claim 17, wherein said other antimalarial agent is one or more medicaments selected from the group consisting of quinine hydrochloride, chloroquine, mefloquine, a sulfadoxine/pyrimethamine combination agent, an atovaquone/proguanil combination agent, artemisinin, artesunate, artemether, an artemether/lumefantrine combination agent and an artesunate/amodiaquine combination agent.

### Claim 19

A method of treating infectious disease caused by hemocytozoon, comprising administering, to a vertebrate in need thereof, an effective amount of a nutrition composition comprising:
(a) one or more amino acids selected from the group consisting of tryptophan, methionine, phenylalanine, valine, leucine, histidine, lysine, and threonine; and
(b) optionally isoleucine, wherein when said isoleucine is present, it is present in an amount of not more than 1.5 wt % relative to the total amount of the nutrition composition.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the nutrition composition does not contain isoleucine.

### Claim 21 (depends on 19)

The method according to claim 19, further comprising one or more nutrients selected from the group consisting of carbohydrate, protein, fat, vitamin and mineral.

### Claim 22 (depends on 19)

The method according to claim 19, wherein the hemocytozoon is a malaria parasite.

### Claim 23 (depends on 19)

The method according to claim 19, further comprising administering an effective amount of other antimalarial agent(s).

### Claim 24 (depends on 23)

The method according to claim 23, wherein said other antimalarial agent is one or more medicaments selected from the group consisting of quinine hydrochloride, chloroquine, mefloquine, a sulfadoxine/pyrimethamine combination agent, an atovaquone/proguanil combination agent, artemisinin, artesunate, artemether, an artemether/lumefantrine combination agent and an artesunate/amodiaquine combination agent.

### Claim 25

A method of treating infectious disease caused by hemocytozoon, comprising administering, to a vertebrate in need thereof, an effective amount of a nutrition composition comprising:
(a) one or more amino acids selected from the group consisting of tryptophan, methionine, phenylalanine, valine, leucine, histidine, lysine, and threonine; and
(b) optionally isoleucine, wherein when said isoleucine is present, it is present in an amount of not more than 3.8 wt % relative to the total amount of the amino acids.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the nutrition composition does not contain isoleucine.

### Claim 27 (depends on 25)

The method according to claim 25, further comprising one or more nutrients selected from the group consisting of carbohydrate, protein, fat, vitamin and mineral.

### Claim 28 (depends on 25)

The method according to claim 25, wherein the hemocytozoon is a malaria parasite.

### Claim 29 (depends on 25)

The method according to claim 25, further comprising administering an effective amount of other antimalarial agent(s).

### Claim 30 (depends on 29)

The method according to claim 29, wherein said other antimalarial agent is one or more medicaments selected from the group consisting of quinine hydrochloride, chloroquine, mefloquine, a sulfadoxine/pyrimethamine combination agent, an atovaquone/proguanil combination agent, artemisinin, artesunate, artemether, an artemether/lumefantrine combination agent and an artesunate/amodiaquine combination agent.
